查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1387209

Adalimumab生物相似藥市場報告：2030 年趨勢、預測與競爭分析

Adalimumab Biosimilar Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

Adalimumab生物相似藥的趨勢和預測

預計到 2030 年，全球Adalimumab生物相似藥市場預計將達到 27.9 億美元，2024 年至 2030 年年複合成長率為 21.6%。這個市場的主要促進因素是關節炎藥物的流行以及皮膚病的增加。全球Adalimumab生物相似藥市場的未來看起來充滿希望，醫院藥房和零售藥房市場充滿機會。

Adalimumab生物相似藥市場洞察

Lucintel 預測 Exemptia 預計將在預測期內實現最高成長。

這是因為Adalimumab生物相似藥用於治療多種自體免疫疾病，並且通常由醫院內的專家進行管理。

由於隨著老年人口的增加，類風濕性關節炎的盛行率不斷增加，在預測期內，北美將繼續成為最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球Adalimumab生物相似藥市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球Adalimumab生物相似藥市場趨勢（2018-2023）與預測（2024-2030）
  • 全球Adalimumab生物相似藥市場（按產品）
    • Exemptia
    • Adalirel
    • Cipleumab
    • 其他
  • 全球Adalimumab生物相似藥市場（依最終用途）
    • 醫院藥房
    • 零售藥房
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球Adalimumab生物相似藥市場區域分佈
  • 北美Adalimumab生物相似藥市場
  • 歐洲Adalimumab生物相似藥市場
  • 亞太阿達木Adalimumab生物相似藥市場
  • 其他區域Adalimumab生物相似藥市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球Adalimumab生物相似藥市場成長機會（按產品）
    • 全球Adalimumab生物相似藥市場成長機會（以最終用途）
    • 全球Adalimumab生物相似藥市場按地區成長機會
  • 全球Adalimumab生物相似藥市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 全球Adalimumab生物相似藥市場產能擴張
    • 全球Adalimumab生物相似藥市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • Alfred E. Tiefenbacher
  • Amgen
  • Boehringer Ingelheim
  • Glenmark
  • Zydus
  • Torrent Pharmaceuticals
  • Reliance Life Sciences
簡介目錄

Adalimumab Biosimilar Trends and Forecast

The future of the global adalimumab biosimilar market looks promising with opportunities in the hospitals pharmacy and retail pharmacy markets. The global adalimumab biosimilar market is expected to reach an estimated $2.79 billion by 2030 with a CAGR of 21.6% from 2024 to 2030. The major drivers for this market are the growing incidence of arthritis drugs along with rising number of skin disorders.

A more than 150-page report is developed to help in your business decisions.

Adalimumab Biosimilar by Segment

The study includes a forecast for the global adalimumab biosimilar by product, end use, and region.

Adalimumab Biosimilar Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Exemptia
  • Adalirel
  • Cipleumab
  • Others

Adalimumab Biosimilar Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Others

Adalimumab Biosimilar Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Adalimumab Biosimilar Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies adalimumab biosimilar companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the adalimumab biosimilar companies profiled in this report include-

  • Alfred E. Tiefenbacher
  • Amgen
  • Boehringer Ingelheim
  • Glenmark
  • Zydus
  • Torrent Pharmaceuticals
  • Reliance Life Sciences

Adalimumab Biosimilar Market Insights

Lucintel forecasts that exemptia is expected to witness the highest growth over the forecast period.

Within this market, hospitals pharmacies is expected to remain the largest segment due to the fact that adalimumab biosimilars are used to treat a variety of autoimmune diseases, which are typically managed by specialists in hospital settings.

North America will remain the largest region during the forecast period due to the growing prevalence of rheumatoid arthritis along with the rise in the geriatric population.

Features of the Global Adalimumab Biosimilar Market

Market Size Estimates: Adalimumab biosimilar market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Adalimumab biosimilar market size by product, end use, and region in terms of value ($B).

Regional Analysis: Adalimumab biosimilar market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, end uses, and regions for the adalimumab biosimilar market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the adalimumab biosimilar market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the adalimumab biosimilar market size?

Answer: The global adalimumab biosimilar market is expected to reach an estimated $2.79 billion by 2030.

Q2. What is the growth forecast for adalimumab biosimilar market?

Answer: The global adalimumab biosimilar market is expected to grow with a CAGR of 21.6% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the adalimumab biosimilar market?

Answer: The major drivers for this market are the growing incidence of arthritis drugs along with rising number of skin disorders.

Q4. What are the major segments for adalimumab biosimilar market?

Answer: The future of the adalimumab biosimilar market looks promising with opportunities in the hospitals pharmacy and retail pharmacy markets.

Q5. Who are the key adalimumab biosimilar market companies?

Answer: Some of the key adalimumab biosimilar companies are as follows:

  • Alfred E. Tiefenbacher
  • Amgen
  • Boehringer Ingelheim
  • Glenmark
  • Zydus
  • Torrent Pharmaceuticals
  • Reliance Life Sciences

Q6. Which adalimumab biosimilar market segment will be the largest in future?

Answer: Lucintel forecasts that exemptia is expected to witness the highest growth over the forecast period.

Q7. In adalimumab biosimilar market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region during the forecast period due to the growing prevalence of rheumatoid arthritis along with the rise in the geriatric population.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the adalimumab biosimilar market by product (exemptia, adalirel, cipleumab, and others), end use (hospitals pharmacies, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Adalimumab Biosimilar Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Adalimumab Biosimilar Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Adalimumab Biosimilar Market by Product
    • 3.3.1: Exemptia
    • 3.3.2: Adalirel
    • 3.3.3: Cipleumab
    • 3.3.4: Others
  • 3.4: Global Adalimumab Biosimilar Market by End Use
    • 3.4.1: Hospitals Pharmacies
    • 3.4.2: Retail Pharmacies
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Adalimumab Biosimilar Market by Region
  • 4.2: North American Adalimumab Biosimilar Market
    • 4.2.2: North American Adalimumab Biosimilar Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others
  • 4.3: European Adalimumab Biosimilar Market
    • 4.3.1: European Adalimumab Biosimilar Market by Product: Exemptia, Adalirel, Cipleumab, and Others
    • 4.3.2: European Adalimumab Biosimilar Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others
  • 4.4: APAC Adalimumab Biosimilar Market
    • 4.4.1: APAC Adalimumab Biosimilar Market by Product: Exemptia, Adalirel, Cipleumab, and Others
    • 4.4.2: APAC Adalimumab Biosimilar Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others
  • 4.5: ROW Adalimumab Biosimilar Market
    • 4.5.1: ROW Adalimumab Biosimilar Market by Product: Exemptia, Adalirel, Cipleumab, and Others
    • 4.5.2: ROW Adalimumab Biosimilar Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Adalimumab Biosimilar Market by Product
    • 6.1.2: Growth Opportunities for the Global Adalimumab Biosimilar Market by End Use
    • 6.1.3: Growth Opportunities for the Global Adalimumab Biosimilar Market by Region
  • 6.2: Emerging Trends in the Global Adalimumab Biosimilar Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Adalimumab Biosimilar Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Adalimumab Biosimilar Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Alfred E. Tiefenbacher
  • 7.2: Amgen
  • 7.3: Boehringer Ingelheim
  • 7.4: Glenmark
  • 7.5: Zydus
  • 7.6: Torrent Pharmaceuticals
  • 7.7: Reliance Life Sciences